Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cassie Mandala

Physician Assistant Geneva, IL Physician Assistant

NPI 1932383445 CMS profile 10648178

2525 Kaneville Rd, Geneva, IL 60134

Open in the dashboard

General payments

$55,113

102 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cassie Mandala of Geneva, IL is reported in the CMS Open Payments database as having received $55,113 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,772 5
2024 General $2,899 7
2023 General $17,037 27
2022 General $15,426 24
2021 General $16,980 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cassie Mandala
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Cassie Mandala were reported at $2,772. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Cassie Mandala Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $16,980 $132 $37–$438 $132
2022 $15,426 $155 $48–$522 $149
2023 $17,037 $167 $52–$557 $160
2024 $2,899 $178 $55–$600 $164
2025 $2,772 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medical Device Business Services, Inc. $50,925 74 payments
  2. Arthrex, Inc. $2,937 10 payments
  3. DePuy Synthes Sales Inc. $460 8 payments
  4. Medwest Associates $233 1 payment
  5. Revance Therapeutics, Inc. $148 1 payment
  6. Stryker Corporation $122 1 payment
  7. Globus Medical, Inc. $116 1 payment
  8. Terumo BCT, Inc. $69 2 payments
  9. Flexion Therapeutics, Inc. $60 2 payments
  10. Vericel Corporation $24 1 payment
  11. Other $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $43,564 31 payments
  2. Travel and Lodging $5,933 31 payments
  3. Food and Beverage $3,215 38 payments
  4. Education $2,400 2 payments
Products named General payments · program years 2021–2025
  1. MONOVISC $4,273 19 payments
  2. ORTHOVISC $4,172 21 payments
  3. PEAK $1,559 4 payments
  4. DAXXIFY $148 1 payment
  5. CINCHLOCK $122 1 payment
  6. Proximal Humerus Strut $116 1 payment
  7. Troch Nail $116 1 payment
  8. Zilretta $60 2 payments
  9. HARVEST BMAC $56 1 payment
  10. MACI $24 1 payment
  11. Other $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$38,074

Of which drugs: $26,365

Medicare patients

89

Average age 75

Services billed

2,484

60 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 27%
Ischemic heart disease 24%
Atrial fibrillation 21%
Diabetes 20%
Cancer 16%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 16 913 $12,329
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 13 608 $8,283
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 152 $104

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record